188ÌåÓý

Professor Gerry Hanna is the Marie Curie Chair of Clinical Oncology at Trinity College Dublin and a Consultant in Radiation Oncology at the St Lukes Radiation Oncology Network and at the Trinity St James Cancer Institute. Gerry also holds honorary appointments at the Peter MacCallum Cancer Centre, Melbourne, the University of Melbourne and Queen’s University Belfast.

Prof. Hanna completed his undergraduate training at Queen’s University Belfast and his postgraduate training at the Cancer Centre, Belfast City Hospital. Following his PhD fellowship, Prof Hanna was awarded the Royal College of Radiologists� Keith Durrant Memorial Travelling Fellowship to undertake a fellowship at the Vrije University Medical Centre in Amsterdam. Prior to taking up his current post, Prof Hanna was Chair of Division for Cancer and Specialist Medicine at Belfast Health and Social Care Trust and prior to this was the Director of Radiation Oncology at the Peter MacCallum Cancer Centre, Melbourne.

• Lung Cancer
• Breast Cancer
• Conventional Radiotherapy
• IMRT/VMAT
• Stereotactic Radiotherapy
• Re-Irradiation
• Drug and Radiotherapy Combinations
• Clinical Leadership

• Fellow of the Royal Australian and New Zealand College of Radiologists.
• Fellow of the Royal College of Radiologists of London.
• Honorary Fellow of the Faculty of Radiology of Radiology and Radiation Oncology, Royal College of Surgeons of Ireland.
• Fellow of the Ulster Medical Society.
• Supporting Ambassador of the European Society for Therapeutic Radiology and Oncology (ESTRO).
• Founding Board Member of the Thoracic Oncology Group of Australasia.
• Member of the Royal College of Physicians of London.
• Member of the British Medical Association.
• Member of American Society for Therapeutic Radiology and Oncology (ASTRO).
• Member of the Trans-Tasmanian Radiation Oncology Group (TROG).
• Member of Cancer Trials Ireland (All-Ireland Cooperative Oncology Research Group) and Lung Cancer DSSG Co-Chair.
• Member of British Thoracic Oncology Group (BTOG).
• Member of International Society for the Study of Lung Cancer (IASLC).
• Member of ESTRO Lung Focus Group 2024-2027

Prof Hanna’s research interests include the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy. He was the chief investigator of the Peter Mac ACRF Radiation Immuno-oncology Program and the International Atomic Energy Agency’s “PERTAIN� study. He is a TMG member for the UK’s HALT, SARON, CONFIRM, ISOTOXIC IMRT and CONCORDE studies.